Evidence map›Paper›PMID 28087406›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2017

Erythrocyte membrane-coated nanogel for combinatorial antivirulence and responsive antimicrobial delivery against Staphylococcus aureus infection.

Yue Zhang, Jianhua Zhang, Wansong Chen, Pavimol Angsantikul, Kevin A Spiekermann, Ronnie H Fang, Weiwei Gao, Liangfang Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 190 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yue ZhangDepartment of Nanoengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Jianhua ZhangDepartment of Nanoengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Department of Polymer Science and Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.
Wansong ChenDepartment of Nanoengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Department of Applied Chemistry, School of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan 410083, China.
Pavimol AngsantikulDepartment of Nanoengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Kevin A SpiekermannDepartment of Nanoengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Ronnie H FangDepartment of Nanoengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Weiwei GaoDepartment of Nanoengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Liangfang ZhangDepartment of Nanoengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: zhang@ucsd.edu.
University of California San Diego · USCentral South University · CNTianjin University of Science and Technology · CN

Funding

Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma MetastasisR01CA200574 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LI, SHULIN, ZHANG, LIANGFANG · 2016 to 2020
$1.8M
Nanotherapeutics for Ocular InfectionsR01EY025947 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C, ZHANG, LIANGFANG · 2015 to 2017
$1.1M
NCI NIH HHS R01 CA200574NEI NIH HHS R01 EY025947
6 · The paper itself

Abstract

We reported an erythrocyte membrane-coated nanogel (RBC-nanogel) system with combinatorial antivirulence and responsive antibiotic delivery for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection. RBC membrane was coated onto the nanogel via a membrane vesicle templated in situ gelation process, whereas the redox-responsiveness was achieved by using a disulfide bond-based crosslinker. We demonstrated that the RBC-nanogels effectively neutralized MRSA-associated toxins in extracellular environment and the toxin neutralization in turn promoted bacterial uptake by macrophages. In intracellular reducing environment, the RBC-nanogels showed an accelerated drug release profile, which resulted in more effective bacterial inhibition. When added to the macrophages infected with intracellular MRSA bacteria, the RBC-nanogels significantly inhibited bacterial growth compared to free antibiotics and non-responsive nanogel counterparts. These results indicate the great potential of the RBC-nanogel system as a new and effective antimicrobial agent against MRSA infection.

Indexed as

Erythrocyte MembraneAnimalsAnti-Bacterial AgentsBacterial ToxinsDrug LiberationGelsHemolysin ProteinsMacrophagesMaleMethicillin-Resistant Staphylococcus aureusMice, Inbred ICRNanoparticlesStaphylococcal InfectionsVancomycinAnti-Bacterial AgentsBacterial ToxinsGelsHemolysin Proteinsstaphylococcal alpha-toxinVancomycinAntibiotic deliveryCell membrane coatingDetoxificationNanomedicineStaph infection

Identifiers

PMID28087406
PMCPMC5503807
OpenAlexW2570207263

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.